Atea Pharmaceuticals (AVIR) Current Deferred Revenue (2020 - 2021)
Atea Pharmaceuticals (AVIR) recorded quarterly Current Deferred Revenue of $192.2 million in Q3 2021, down 14.58% quarter-over-quarter from $225.0 million in Q2 2021.
Atea Pharmaceuticals (AVIR) Current Deferred Revenue (2020 - 2021) Analysis & Trends
Atea Pharmaceuticals' Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $192.2 million for Q3 2021.
- In Q3 2021, Current Deferred Revenue changed N/A year-over-year to $192.2 million; the TTM figure through Sep 2021 stood at $192.2 million (changed N/A YoY), while the FY2020 annual figure was $301.4 million, changed N/A from the prior year.
- Current Deferred Revenue was $192.2 million for Q3 2021 at Atea Pharmaceuticals, down from $225.0 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $301.4 million in Q4 2020 to a low of $192.2 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Atea Pharmaceuticals | 347.28 Mn | 347.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 192.18 Mn |
| Jun 30, 2021 | 224.99 Mn |
| Mar 31, 2021 | 235.38 Mn |
| Dec 31, 2020 | 301.37 Mn |